| Jacqueline Krzanik, NP | |
|
140 Hospital Dr, Suite 215, Bennington, VT 05201-5009 | |
| (802) 442-4785 | |
| (802) 447-3459 |
| Full Name | Jacqueline Krzanik |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 140 Hospital Dr, Bennington, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710949045 | NPI | - | NPPES |
| 1012144 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1010031947 (Vermont) | Primary |
| Entity Name | Southwestern Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184994162 PECOS PAC ID: 0143138446 Enrollment ID: O20120613000217 |
News Archive
Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.
More than half a million children in the U.S. sustain a traumatic brain injury (TBI) every year. Adults who suffer TBI often report headaches afterward, but little is known about how often children suffer headaches after similar injuries. In a significant new study, "Headache After Pediatric Traumatic Brain Injury: A Cohort Study," researchers analyzed the prevalence of headaches three and 12 months after mild, moderate or severe TBI in children ages 5 to 17, and discovered the risk of headache was higher in adolescents (ages 13 to 17) and in girls.
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.
At a time when hospital operating margins are paper thin, the Premier healthcare alliance is helping its members achieve enhanced savings through its hospital group buy program. Members who utilized the program generated savings of more than $74 million in 2008.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacqueline Krzanik, NP 140 Hospital Dr, Suite 215, Bennington, VT 05201-5009 Ph: (802) 442-4785 | Jacqueline Krzanik, NP 140 Hospital Dr, Suite 215, Bennington, VT 05201-5009 Ph: (802) 442-4785 |
News Archive
Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.
More than half a million children in the U.S. sustain a traumatic brain injury (TBI) every year. Adults who suffer TBI often report headaches afterward, but little is known about how often children suffer headaches after similar injuries. In a significant new study, "Headache After Pediatric Traumatic Brain Injury: A Cohort Study," researchers analyzed the prevalence of headaches three and 12 months after mild, moderate or severe TBI in children ages 5 to 17, and discovered the risk of headache was higher in adolescents (ages 13 to 17) and in girls.
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.
At a time when hospital operating margins are paper thin, the Premier healthcare alliance is helping its members achieve enhanced savings through its hospital group buy program. Members who utilized the program generated savings of more than $74 million in 2008.
› Verified 1 days ago
Melissa Rowe, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 655 Main St, Bennington, VT 05201 Phone: 802-447-2343 Fax: 802-442-4636 | |
Mrs. Stacey K Whitten, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 325 North St, Bennington, VT 05201 Phone: 802-447-6913 | |
Aimee Bullettsmith, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 140 Hospital Dr, Suite 215, Bennington, VT 05201 Phone: 802-442-2997 Fax: 802-447-0635 | |
Stephanie Sauer, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 100 Hospital Dr, Bennington, VT 05201 Phone: 802-447-5025 | |
Mrs. Whitney P Mical, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 655 Main St, Suite 1, Bennington, VT 05201 Phone: 802-447-2343 Fax: 802-442-4636 | |
Jo L Dowling, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 140 Hospital Dr, Suite 215, Bennington, VT 05201 Phone: 802-442-4785 Fax: 802-447-3459 | |
Rebecca Filson, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Drive, Box 65, Bennington, VT 05201 Phone: 802-447-5023 |